Answers are grounded in this paper and cite their sources.
Baricitinib improved clinical signs and symptoms in patients with moderate-to-severe AD within 16 weeks of treatment and induced rapid reduction of itch. The safety profile remained consistent with prior findings from baricitinib clinical development in AD, with no new safety concerns.
No takes yet. Share an insight, caveat, or question.
Simpson et al. (2020) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: